M&A
Viyash Life Sciences acquires controlling stake in API manufacturer Symed Labs
In one of the largest transactions in the API (Active Pharmaceutical Ingredient) space, Viyash Life Sciences Pvt Ltd - a pharma platform backed by global PE investor Carlyle Group - has acquired a controlling stake in fellow Hyderabad-based Symed Labs. Veda Corporate Advisors was the exclusive financial advisor to Symed and its promoters. Established in 1997, Symed is an API manufacturer focused on niche products across therapy segments such as anti-bacterial, antihistamine, anti-inflammatory, antipsychotic, and anticonvulsant. It operates five plants and an R&D unit, all located around Hyderabad.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
